Adults receiving nimacimab plus semaglutide had a greater reduction in weight at 26 weeks than adults receiving semaglutide alone in intention-to-treat analysis (mean difference, 2.95 percentage points
Post-injection care: Withdraw the needle smoothly at the same angle of insertion
Clinical studies have shown GLP-1 receptor agonists may reduce high-sensitivity C-reactive protein (hs-CRP), tumour necrosis factor-alpha (TNF-), interleukin-6 (IL-6), and interleukin-1 beta (IL-1)
Related articles Novo cuts Wegovy prices as Mounjaro launches, but local options and adherence will decide the winner G2G Bio to expand long-acting injectable platform with IPO [Reporters Notebook] Sam Chun Dang Pharms misleading hype over oral GLP-1 trial data ProGen's differentiation strategy for its obesity drug is 'muscle preservation and gut health' Daewoong Pharm marks record-breaking performance driven by new drugs and global expansion plan Daewoong Pharmaceutical leads consortium to develop once-monthly obesity drug Daewoong Pharmaceutical secures IND approval for dissolvable microneedle growth hormone patch Korean lawmaker proposes adding obesity treatment to Public Health Act Daewoong pushes semaglutide into patches with phase 1 trial launch in Korea Daewoong confirms safety and continued progress of P2 trial for IPF drug Daewoong licenses microneedle technology to push into obesity therapeutics Kim Ji-hye [email protected]
During this visit, bring your current medication list, including the exact GLP-1 product, dose, and administration schedule
